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Introduction: The infusion of 2 partially HLA-matched um-
bilical cord blood (UCB) is a potential strategy for extending
UCB transplantation to more patients. The risk and beneﬁts
of double UCB transplantation (dUCBT) relative to those
observed after transplantation with related and unrelated
adult donors remains to be determined.
Methods: Two hundred and eighty three adult patients
undergoing ﬁrst allogeneic transplant for acute myeloid
leukemia (N¼166), acute lymphocytic leukemia (N¼87) and
myelodysplastic syndrome (N¼30) at Singapore General
Hospital (N¼176) and National University Cancer Institute,
Singapore (N¼107) between 2005-2013 were studied. The
patients received transplantation using matched related
donor (MRD, n¼172), matched unrelated donor (MUD,
n¼70) or 4-6/6 HLA matched dUCB (n¼41) graft after mye-
loablative conditioning (MAC, n¼147) or reduced intensity
conditioning (RIC, N¼136), consisting of ﬂudarabine, cyclo-
phosphamide (120 mg/kg for MAC , 50 mg/kg for RIC) and
total body irradiation (12-14 Gy for MAC, 2 Gy for RIC).
Results: The leukemia free survival at 5 years was similar for
each donor type, 43% for dUCB, 45% for MSD and 42% for
MUD (p¼0.26). There was no statistically signiﬁcant differ-
ence in relapse-related death and transplant-related mor-
tality among the 3 donor types. However, when the outcome
was analyzed separately according to conditioning regimen,
a signiﬁcant difference in survival was observed among
patients receiving RIC. As compared to the recipients of MSD
or MUD, the risk of relapse-related death was highest in
recipients of dUCB (HR 2.75, 95% CI 1.05-7.1; p¼0.04) after
RIC, resulting in the lowest overall survival (dUCB 9%; MSD
43%; MUD 29%; p¼0.009). For patients receiving MAC,
leukemia-free survival in patients after dUCBT (59%) was
comparable to that after MSD (46%) and MUD (52%) trans-
plantation (p¼0.82)
Conclusions: Our results support the use of 2 partially HLA-
matched UCB as a suitable alternative for patients without an
available HLA matched donor. However, the use of RIC for
dUCBT is still limited by high incidence of relapse. Future
studies are necessary to deﬁne the best regimen that can
induce sustained engraftment without increasing the risk of
relapse and regimen-related toxicity.382
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Introduction: In adult patients with high risk ALL, deﬁned as
Philadelphia cromosome ALL (Phi+) or slow response to
chemotherapy, sibling donor aHSCT in ﬁrst remission is
recommended as consolidation treatment after achieving a
complete remission. Still is unclear what other subgroup of
adult patients beneﬁt the most from aHSCT.
Objectives: The primary objective was to describe the clin-
ical outcomes of ALL patients after aHSCT in our center,
including overall survival (OS), relapse-free-survival (RFS)
and transplant-related-mortality (TRM) .
Results: Between 1994 and 2013, 37 patients with ALL were
transplanted, 16 Phi+ and 21 Phi-. Two patients had a second
transplant for relapsed ALL Phi+, therefore 39 aHSCT pro-
cedures for ALL have been performed in our center. The
average age is 33 yo (range: 17-56) and 68% were male pa-
tients (n¼25). Phi+ patients weremostly>30 yo (63%, n¼10),
as compared to Phi- that were mostly 30 yo (67%, n¼14).
Most transplants were performed in ﬁrst remission (70%,
n¼22), under myeloablative conditioning regimen in 92%
(n¼34). Reduced intensity conditioning (RIC) regimen was
used because of age (n¼1; Phi-) and relapse (n¼2; Phi+).
GVHD prophylaxis consisted of cyclosporin A and metho-
trexate in all the patients. Among Phi+ patients, 69% (n¼11)
had TKI prior to aHSCT. Only 25% (n¼4) received TKI as
maintenance therapy after aHSCT. Average CD34 dose
collected by leukapheresis was 5.5x106/kg (range:
2,14e9,16x106/kg), with mean platelet engraftment at day 15
after transplant (range: 8-25 days) and mean neutrophil
engraftment at day 16 after transplant (no ﬁlgrastim is used
after transplant) (range: 10-22 days). In Phi+ patients, 3-year
EFS and OS was 49% and 64%, respectively. In Phi- patients 3-
year EFS and OS was 40% and 43%, respectively. One year
TRMwas 14% in Phi- and 21% in Phi+ ALL patients. Univariate
analysis failed to show a correlation between RFS and OS
with pre and post aHSCT minimal residual disease as
measured bymulticolor ﬂow cytometry and PCR (in Phi+ ALL
patientes) or remission status (CR1 vs CR2).
Conclusions: Our data on the outcomes of ALL patients were
consistent with that reported in literature. In our series, OS in
Phi+ patients was superior to those with Phi-, we speculated
that it may be at least in part due to disease erradication by
TKI. Our data support our practice of offering aHSCT early in
the disease course for patients with ALL patients, specially
Ph+ ALL patients.383
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Background: Hematopoietic Stem Cell Transplantation
(HSCT) is a potentially curative treatment for a number of
hematological malignancies and hereditary disorders. How-
ever, patients undergoing HSCT may have serious compli-
cations that require support in an intensive care unit (ICU),
with signiﬁcant associated mortality and reported 6-month
overall survival (OS) less than 5%.
Patients and Methods: Retrospective study of adult patients
undergoing autologous, allogeneic and umbilical cord blood
HSCT between 2007 and 2011 who required ICU transfer at
Table 1





cAUC, mean (range) in mg*h/L 85.3 (45 e 156) 96.2 (74 e 117)
Patients within target cAUC
80 - 100 mg*h/L, n (%)
17 (34%) 35 (70%)
A total exposure of 90 mg*h/L relates to 21.6 mM*min total, or 5400
mM*min/day
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transplant, at the Catholic University Health Network, Chile,
followed 1 year after transplantation.
Results: We analyzed 97 patients, average 37 years old
(range: 15-68 years). Main indications for HSCT were he-
matologic malignancies (84%, n¼82), mainly acute lympho-
blastic leukemia (29%, n¼28), acute myeloid leukemia (21%,
n¼20), non-Hodgkin lymphoma (13%, n¼13) and multiple
myeloma (13%, n¼13). Ninety percent of the patients (n¼87)
received myeloablative conditioning regimens including
drugs like cyclophosphamide, carmustine, melphalan, eto-
poside, busulfan and total body irradiation. Twenty nine
percent of the patients (n¼28/97) were admitted in the ICU
(autologous HSCT: 15% [n: 5/33]; allogeneic HSCT: 32%
[n¼13/41]; cord blood HSCT: 43% [n¼10/23]) with an average
stay of 19 days (range: 1-73 days) (autologous: 13 days,
allogeneic: 16 days, cord blood: 22 days). The median time
from admission to transplant to ICU transfer occurred at day
15 after transplantation (autologous: day 3, allogeneic: day
16, cord blood: day 22). Main causes for admission were
acute respiratory failure (63%), septic shock (19%) and
neurological complications (19%), with similar distribution
between the different types of transplants. Among the pa-
tients admitted to ICU, 20% (n¼1/5) of autologous, 69% (n¼9/
13) of allogeneic and 70% (n¼7/10) of the cord blood HSCT
died in the unit. Patients died in the ICU 108 days average
after transplantation (range: 4-320) (autologous: 10 days,
allogeneic: 131 days, cord blood: 119 days). One-year OS of
patients who survived the ICU vs patients never admitted to
the ICU was 53% and 85%, respectively (p¼0.0036). For
allogeneic HSCT, 1-year OS was 15% vs 85% (p<0.0001), for
cord blood transplantation 1-year OS was 20% vs 84%
(P¼0.0008) and for autologous HSCT 1-year OS was 80% vs
89% (pNS), after comparing patients who survived the ICU vs
patients never admitted to the ICU, respectively.
Conclusions: Although mortality of HSCT recipients
admitted in ICU is high, our results show that intensive
support can be beneﬁcial in about half of patients who were
admitted, with short to medium outcomes not so unfavor-
able than has been previously reported.Figure 1. busulfan exposure for each patient384
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Busulfan (Bu) is an alkylating drug used in conditioning
regimens for hematopoietic cell transplantation (HCT).
Optimal myelo-ablative exposure of Bu is assumed to be 90
mg*h/L when given in combination with ﬂudarabine leading
to optimal (event free) survival rates. Despite the availability
of intravenous Bu instead of the oral formulation, there is still
wide inter-individual variability in Bu pharmacokineticsafter intravenous administration, particularly in children. An
individual dosing nomogram based on a pharmacokinetic
(PK) model has been developed by Bartelink et al (Clin
Pharmacokinet 2012) that is expected to result in more
predictive Bu exposure and thereby to a safer and more
effective conditioning regimen. The aims of this study are to
(i) prospectively investigate target attainment of the dosing
nomogram and (ii) assess the additive value of therapeutic
drug monitoring (TDM).
Methods: Bu was administered once daily in a 3-hour infu-
sion on 4 consecutive days. Drug levels were measured on
day 1 and 4 and Bu exposure was calculated as cumulative
area under the concentration-time curve day 1-4 (cAUC)
using MWPharm 3.60. The accuracy and precision of the
dosing nomogram was assessed by comparing cAUC based
only on model prediction (90 mg*h/L) with the observed
cAUC for each individual patient based on PK data on day 1
(No TDM). Without TDM cAUC was calculated based on PK
data on day 1 extrapolated to day 1-4. With TDM cAUC was
determined on PK data on day 1 and 4, including dose
adjustment. To assess the additive value of TDM the per-
centage patients within target cAUC 80 e 100 mg*h/L were
compared for the situation that no TDMwould be performed
and the situation with TDM.
Results: 50 consecutive pediatric HCT patients (age 3
monthse 18 year) were included between 2011 and 2012. Bu
exposure for each patient is shown in ﬁgure 1. Without TDM
mean cAUC is 85,3 mg*h/L, this corresponds well with the
predicted cAUC of 90 mg*h/L based on the PK model. The
range of cAUC for individual patients however is very large
(table 1). Without TDM only 34% of patients reached target
cAUC and with TDM this was 70% of patients.
Conclusions: This prospective validation shows that the
bodyweight based dosing nomogram overall leads to a mean
Bu exposure of 90 mg*h/L in patients between 3 months and
18 years. Some remaining unexplained variability between
patients and between days, however, still leads to variability
in exposure. Therefore TDM of intravenous Bu is still needed
and of utmost importance to reach optimal target exposure
in pediatric patients in order to optimize outcomes of HCT.
